Luciano Adorini

Q: What Schools Are Affiliated With Luciano Adorini

Luciano Adorini is affiliated with the following schools: University of California, Berkeley, Stanford University, Sapienza University of Rome

Luciano Adorini's AcademicInfluence.com Rankings

Luciano Adorini

Computer Science

#4418

World Rank

#4654

Historical Rank

Computational Linguistics

#418

World Rank

#425

Historical Rank

Machine Learning

#856

World Rank

#868

Historical Rank

Artificial Intelligence

#1065

World Rank

#1084

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Luciano Adorini's Degrees

PhD Computer Science Stanford University
Masters Computer Science University of California, Berkeley
Bachelors Computer Science University of California, Berkeley

Similar Degrees You Can Earn

Why Is Luciano Adorini Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Luciano Adorini's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. (1998) (1356)
1α,25-Dihydroxyvitamin D3 Inhibits Differentiation, Maturation, Activation, and Survival of Dendritic Cells Leading to Impaired Alloreactive T Cell Activation (2000) (1132)
Maturation Stages of Mouse Dendritic Cells in Growth Factor–dependent Long-Term Cultures (1997) (947)
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. (2013) (766)
Regulatory T Cells Induced by 1α,25-Dihydroxyvitamin D3 and Mycophenolate Mofetil Treatment Mediate Transplantation Tolerance1 (2001) (617)
Control of autoimmune diseases by the vitamin D endocrine system (2008) (564)
Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease (2011) (557)
The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. (2002) (498)
Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice (1995) (474)
Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. (2015) (466)
A 1α,25-Dihydroxyvitamin D3 Analog Enhances Regulatory T-Cells and Arrests Autoimmune Diabetes in NOD Mice (2002) (440)
TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. (2011) (440)
Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes. (2000) (422)
Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory T cells by 1,25-dihydroxyvitamin D3. (2005) (419)
Cardiomyocytes induce endothelial cells to trans-differentiate into cardiac muscle: Implications for myocardium regeneration (2001) (399)
Cutting Edge: Selective Usage of Chemokine Receptors by Plasmacytoid Dendritic Cells1 (2001) (371)
The role of Stat4 in species-specific regulation of Th cell development by type I IFNs. (1998) (332)
Calcitriol Suppresses Antiretinal Autoimmunity through Inhibitory Effects on the Th17 Effector Response 1 (2009) (330)
1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. (2000) (310)
The role of IL-12 in the induction of organ-specific autoimmune diseases. (1995) (300)
Leukocyte Recruitment in the Cerebrospinal Fluid of Mice with Experimental Meningitis Is Inhibited by an Antibody to Junctional Adhesion Molecule (Jam) (1999) (296)
Microglia are more efficient than astrocytes in antigen processing and in Th1 but not Th2 cell activation. (1998) (281)
Differential migration behavior and chemokine production by myeloid and plasmacytoid dendritic cells. (2002) (279)
Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. (2007) (270)
IL-12 production by central nervous system microglia is inhibited by astrocytes. (1997) (265)
Inhibition of Th1 development and treatment of chronic‐relapsing experimental allergic encephalomyelitis by a non‐hypercalcemic analogue of 1,25‐dihydroxyvitamin D3 (2000) (258)
Dynamics of Pathogenic and Suppressor T Cells in Autoimmune Diabetes Development (2003) (257)
1,25-Dihydroxyvitamin D3 Selectively Modulates Tolerogenic Properties in Myeloid but Not Plasmacytoid Dendritic Cells1 (2007) (257)
Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development (2019) (256)
The control of T cell responses by dendritic cell subsets. (2000) (252)
IL-12: a key cytokine in immune regulation. (1996) (244)
Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. (2012) (242)
Mechanisms influencing the immunodominance of T cell determinants (1988) (235)
In vivo competition between self peptides and foreign antigens in T-cell activation (1988) (218)
Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. (1993) (217)
Cutting Edge: Differential Chemokine Production by Myeloid and Plasmacytoid Dendritic Cells1 (2002) (215)
Selective development of T helper (Th)2 cells induced by continuous administration of low dose soluble proteins to normal and beta(2)- microglobulin-deficient BALB/c mice (1996) (212)
Dendritic cells as key targets for immunomodulation by Vitamin D receptor ligands (2004) (211)
Dendritic cell tolerogenicity: a key mechanism in immunomodulation by vitamin D receptor agonists. (2009) (208)
Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. (2009) (208)
Regulatory T Cells Induced by 1 ,25-Dihydroxyvitamin D3 and Mycophenolate Mofetil Treatment Mediate Transplantation Tolerance (2001) (206)
Caspase-1 regulates the inflammatory process leading to autoimmune demyelination. (1999) (206)
Dual farnesoid X receptor/TGR5 agonist INT‐767 reduces liver injury in the Mdr2−/− (Abcb4−/−) mouse cholangiopathy model by promoting biliary HCO 3− output (2011) (205)
Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. (2004) (204)
Intervention in autoimmunity: the potential of vitamin D receptor agonists. (2005) (202)
Intrathecal Delivery of IFN-γ Protects C57BL/6 Mice from Chronic-Progressive Experimental Autoimmune Encephalomyelitis by Increasing Apoptosis of Central Nervous System-Infiltrating Lymphocytes1 (2001) (201)
A 1alpha,25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. (2002) (199)
A Vitamin D Analog Down-Regulates Proinflammatory Chemokine Production by Pancreatic Islets Inhibiting T Cell Recruitment and Type 1 Diabetes Development1 (2004) (190)
Tolerogenic Dendritic Cells Induced by Vitamin D Receptor Ligands Enhance Regulatory T Cells Inhibiting Autoimmune Diabetes (2003) (189)
Restructuring of the Gut Microbiome by Intermittent Fasting Prevents Retinopathy and Prolongs Survival in db/db Mice (2018) (187)
Fine specificity of regulatory T cells. II. Suppressor and helper T cells are induced by different regions of hen egg-white lysozyme in a genetically nonresponder mouse strain (1979) (182)
Bile Acid Receptor Activation Modulates Hepatic Monocyte Activity and Improves Nonalcoholic Fatty Liver Disease* (2013) (180)
A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis (2018) (176)
Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. (2012) (170)
Functional Maturation of Adult Mouse Resting Microglia into an APC Is Promoted by Granulocyte-Macrophage Colony-Stimulating Factor and Interaction with Th1 Cells1 (2000) (165)
Suppressive Effect of 1α,25-Dihydroxyvitamin D3 on Type I IFN-Mediated Monocyte Differentiation into Dendritic Cells: Impairment of Functional Activities and Chemotaxis1 (2005) (165)
Determinant capture as a possible mechanism of protection afforded by major histocompatibility complex class II molecules in autoimmune disease (1993) (164)
Unique Regulation of CCL18 Production by Maturing Dendritic Cells1 (2003) (161)
Functional Characterization of the Semisynthetic Bile Acid Derivative INT-767, a Dual Farnesoid X Receptor and TGR5 Agonist (2010) (160)
Immunomodulatory effects of vitamin D receptor ligands in autoimmune diseases. (2002) (156)
Human Benign Prostatic Hyperplasia Stromal Cells As Inducers and Targets of Chronic Immuno-Mediated Inflammation1 (2009) (154)
Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases. (2004) (152)
Dendritic cells are the most efficient in presenting endogenous naturally processed self-epitopes to class II-restricted T cells. (1995) (152)
Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model (2010) (149)
Different Functional Specificity Repertoires for Suppressor and Helper T Cells (1978) (149)
Inflammation in multiple sclerosis: the good, the bad, and the complex (2002) (143)
The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria. (2009) (140)
Capacity of intact proteins to bind to MHC class II molecules. (1989) (133)
Relative efficiency of microglia, astrocytes, dendritic cells and B cells in naive CD4+ T cell priming and Th1/Th2 cell restimulation (1999) (132)
Cutting Edge: Proangiogenic Properties of Alternatively Activated Dendritic Cells1 (2005) (131)
Deviation of pancreas‐infiltrating cells to Th2 by interleukin‐12 antagonist administration inhibits autoimmune diabetes (1997) (130)
Understanding autoimmune diabetes: insights from mouse models. (2002) (127)
Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells. (2012) (123)
Th1 and Th2 cells. (1998) (120)
Acceleration of intracellular targeting of antigen by the B‐cell antigen receptor: importance depends on the nature of the antigen–antibody interaction (1997) (119)
Induction of tolerogenic dendritic cells by vitamin D receptor agonists. (2009) (113)
Treatment of Experimental Autoimmune Prostatitis in Nonobese Diabetic Mice by the Vitamin D Receptor Agonist Elocalcitol1 (2006) (111)
Dendritic cells but not B cells present antigenic complexes to class II- restricted T cells after administration of protein in adjuvant (1996) (110)
Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide. (2003) (108)
Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases (2003) (105)
Farnesoid X receptor activation increases reverse cholesterol transport by modulating bile acid composition and cholesterol absorption in mice (2016) (103)
Human bladder as a novel target for vitamin D receptor ligands. (2005) (102)
Induction of macrophage-derived chemokine/CCL22 expression in experimental autoimmune encephalomyelitis and cultured microglia: implications for disease regulation (2002) (101)
Pancreas-infiltrating Th1 cells and diabetes develop in IL-12-deficient nonobese diabetic mice. (1999) (100)
A Peptide-binding Motif for I-Ag7, the Class II Major Histocompatibility Complex (MHC) Molecule of NOD and Biozzi AB/H Mice (1997) (100)
IL-12 Administration Accelerates Autoimmune Diabetes in Both Wild-Type and IFN-γ-Deficient Nonobese Diabetic Mice, Revealing Pathogenic and Protective Effects of IL-12-Induced IFN-γ1 (2003) (98)
The vitamin D receptor agonist elocalcitol inhibits IL‐8‐dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF‐kB pathways (2009) (98)
CD40-CD154 interaction and IFN-gamma are required for IL-12 but not prostaglandin E2 secretion by microglia during antigen presentation to Th1 cells. (1999) (95)
Hepatic carboxylesterase 1 is essential for both normal and farnesoid X receptor‐controlled lipid homeostasis (2014) (94)
G Protein-Coupled Bile Acid Receptor TGR5 Activation Inhibits Kidney Disease in Obesity and Diabetes. (2016) (93)
Glia-T cell dialogue (2000) (91)
Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia. (2004) (91)
Peptide competition for antigen presentation. (1990) (91)
FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity. (2017) (89)
Competition for antigen presentation in living cells involves exchange of peptides bound by class II MHC molecules (1989) (89)
Vitamin D endocrine system and the immune response in rheumatic diseases. (2011) (88)
Th1 cells induce and Th2 inhibit antigen‐dependent IL‐12 secretion by dendritic cells (1998) (88)
IL-10 is required for development of protective Th1 responses in IL-12-deficient mice upon Candida albicans infection. (1998) (86)
Interaction of an immunodominant epitope with Ia molecules in T-cell activation. (1988) (83)
Central nervous system gene therapy with interleukin-4 inhibits progression of ongoing relapsing–remitting autoimmune encephalomyelitis in Biozzi AB/H mice (2001) (83)
Farnesoid X receptor activation improves erectile function in animal models of metabolic syndrome and diabetes. (2011) (81)
The Frequency of High Avidity T Cells Determines the Hierarchy of Determinant Spreading1 (2001) (81)
Efficient immune responses in mice lacking N‐region diversity (1995) (80)
The fine specificity of regulatory T cells IV. Idiotypic complementarity and antigen‐bridging interactions in the anti‐lysozyme response (1979) (79)
Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol) (2007) (78)
Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease. (2010) (77)
BXL‐628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human bladder (2007) (76)
Inhibition by brefeldin A of presentation of exogenous protein antigens to MHC class II-restricted T cells (1990) (76)
Antigen presentation of hen egg‐white lysozyme but not of ribonuclease A is augmented by the major histocompatibility complex class II‐associated invariant chain (1991) (74)
Interleukin-12, a key cytokine in Th1-mediated autoimmune diseases (1999) (73)
Metabolic syndrome induces inflammation and impairs gonadotropin-releasing hormone neurons in the preoptic area of the hypothalamus in rabbits (2014) (73)
The vitamin D receptor as a therapeutic target (2006) (71)
Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome (2012) (71)
FXR-Dependent Modulation of the Human Small Intestinal Microbiome by the Bile Acid Derivative Obeticholic Acid. (2018) (70)
Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR (2018) (69)
Secretory defects induced by immunosuppressive agents on human pancreatic β-cells (2002) (69)
Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: An experimental study in the rabbit (2014) (69)
Manipulation of the Th1/Th2 cell balance: an approach to treat human autoimmune diseases? (1996) (68)
1,25-Dihydroxyvitamin D3 analogs as potential therapies in transplantation. (2002) (68)
Prevention of autoimmune diabetes in non-obese diabetic mice by treatment with a class II major histocompatibility complex-blocking peptide (1993) (68)
Structural requirements for the interaction between peptide antigens and I-Ed molecules. (1989) (67)
FXR and TGR5 Agonists Ameliorate Liver Injury, Steatosis, and Inflammation After Binge or Prolonged Alcohol Feeding in Mice (2018) (66)
Ultrasonographic and clinical correlates of seminal plasma interleukin-8 levels in patients attending an andrology clinic for infertility. (2011) (64)
Exogenous peptides compete for the presentation of endogenous antigens to major histocompatibility complex class II-restricted T cells (1991) (64)
The ependymal route to the CNS: an emerging gene-therapy approach for MS. (2001) (63)
Elevated body mass index correlates with higher seminal plasma interleukin 8 levels and ultrasonographic abnormalities of the prostate in men attending an andrology clinic for infertility (2011) (63)
The fine specificity of regulatory T cells. I. Hen egg-white lysozyme-induced suppressor T cells in a genetically nonresponder mouse strain do not recognize a closely related immunogenic lysozyme. (1979) (63)
Lysozyme-induced T-suppressor cells and antibodies have a predominant idiotype (1979) (62)
Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia (2010) (62)
Elocalcitol inhibits inflammatory responses in human thyroid cells and T cells. (2008) (61)
Animal models of spontaneous autoimmune disease: type 1 diabetes in the nonobese diabetic mouse. (2007) (59)
Epitope-specific enhancement of antigen presentation by invariant chain (1993) (57)
Central nervous system delivery of interleukin 4 by a nonreplicative herpes simplex type 1 viral vector ameliorates autoimmune demyelination. (1998) (57)
Failure to demonstrate long-lived MHC saturation both in vitro and in vivo. Implications for therapeutic potential of MHC-blocking peptides. (1994) (57)
Delivery to the central nervous system of a nonreplicative herpes simplex type 1 vector engineered with the interleukin 4 gene protects rhesus monkeys from hyperacute autoimmune encephalomyelitis. (2001) (57)
Interleukin 12 and autoimmune diabetes (2001) (57)
Vitamin D receptor agonists inhibit pro-inflammatory cytokine production from the respiratory epithelium in cystic fibrosis. (2011) (56)
Gemini Vitamin D Analogues Inhibit Estrogen Receptor–Positive and Estrogen Receptor–Negative Mammary Tumorigenesis without Hypercalcemic Toxicity (2008) (56)
FXR activation normalizes insulin sensitivity in visceral preadipocytes of a rabbit model of MetS. (2013) (56)
Processing of an endogenous protein can generate MHC class II-restricted T cell determinants distinct from those derived from exogenous antigen. (1991) (56)
Pathogenesis and immunotherapy of autoimmune diseases. (1997) (55)
Cytokine‐based immunointervention in the treatment of autoimmune diseases (2003) (55)
Spontaneous and Prostatic Steroid Binding Protein Peptide-Induced Autoimmune Prostatitis in the Nonobese Diabetic Mouse1 (2007) (55)
Faculty Opinions recommendation of Murine plasmacytoid dendritic cells initiate the immunosuppressive pathway of tryptophan catabolism in response to CD200 receptor engagement. (2004) (54)
Colon cancer and solar ultraviolet B radiation and prevention and treatment of colon cancer in mice with vitamin D and its Gemini analogs (2005) (54)
Human Immunodeficiency Virus Type 1 gp120 and Other Activation Stimuli Are Highly Effective in Triggering Alpha Interferon and CC Chemokine Production in Circulating Plasmacytoid but Not Myeloid Dendritic Cells (2005) (54)
Atorvastatin but not elocalcitol increases sildenafil responsiveness in spontaneously hypertensive rats by regulating the RhoA/ROCK pathway. (2008) (52)
Early Th1 Response in Unprimed Nonobese Diabetic Mice to the Tyrosine Phosphatase-Like Insulinoma-Associated Protein 2, an Autoantigen in Type 1 Diabetes (2000) (52)
Special attractions for suppressor T cells. (2003) (52)
Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression. (2017) (51)
Inhibition of spontaneous and androgen-induced prostate growth by a nonhypercalcemic calcitriol analog. (2003) (51)
Normal B cells fail to secrete interleukin‐12 (1997) (50)
Soluble protein but not peptide administration diverts the immune response of a clonal CD4+ T cell population to the T helper 2 cell pathway. (1996) (50)
Semisynthetic Bile Acid FXR and TGR5 Agonists: Physicochemical Properties, Pharmacokinetics, and Metabolism in the Rat (2014) (49)
A microcomputer program for probit analysis of interleukin-2 (IL-2) titration data. (1986) (49)
Characterization of T-helper epitopes of the glycoprotein of vesicular stomatitis virus (1994) (49)
Processing of endogenously synthesized hen egg-white lysozyme retained in the endoplasmic reticulum or in secretory form gives rise to a similar but not identical set of epitopes recognized by class II-restricted T cells. (1993) (48)
Selective Effects of Ionizing Radiations on Immunoregulatory Cells (1982) (48)
Why peptides? Their possible role in the evolution of MHC-restricted T-cell recognition. (1989) (47)
Immunotherapeutic approaches in multiple sclerosis (2004) (47)
Manipulating dendritic cells to induce regulatory T cells. (2005) (47)
Central Nervous System Delivery of Interleukin 4 by a Nonreplicative Herpes Simplex Type 1 Viral Vector Ameliorates Autoimmune Demyelination (1998) (45)
Inhibition of Acute and Chronic Allograft Rejection in Mouse Models by BXL-628, a Nonhypercalcemic Vitamin D Receptor Agonist (2005) (45)
The vitamin D receptor agonist elocalcitol upregulates L-type calcium channel activity in human and rat bladder. (2008) (44)
Enhancing effect of IFN-gamma on helper T cell activity and IL 2 production. (1985) (44)
Constitutive presentation of dominant epitopes from endogenous naturally processed self-beta 2-microglobulin to class II-restricted T cells leads to self-tolerance. (1995) (43)
Selective immunosuppression by administration of major histocompatibility complex (MHC) class II-binding peptides. I. Evidence for in vivo MHC blockade preventing T cell activation (1992) (43)
In vivo restoration of T cell functions by human IL-1 beta or its 163-171 nonapeptide in immunodepressed mice. (1988) (42)
Cytokine therapy in immune-mediated demyelinating diseases of the central nervous system: a novel gene therapy approach (2000) (42)
Comparison of structural requirements for interaction of the same peptide with I-Ek and I-Ed molecules in the activation of MHC class II-restricted T cells. (1991) (41)
Reconstitution of T cell functions in aging mice by thymosin α1 (1986) (41)
Polymorphisms in the Il12b gene affect structure and expression of IL-12 in NOD and other autoimmune-prone mouse strains (2002) (41)
Enhanced frequency of mitogen‐responsive T cell precursors in old mice injected with thymosin α1 (1987) (41)
New perspectives on immunointervention in autoimmune diseases. (1990) (40)
Extending SAR of bile acids as FXR ligands: discovery of 23-N-(carbocinnamyloxy)-3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-amine. (2011) (39)
IRF‐4 expression in the human myeloid lineage: up‐regulation during dendritic cell differentiation and inhibition by 1α,25‐dihydroxyvitamin D3 (2005) (38)
The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma (2019) (37)
A dual agonist of farnesoid X receptor (FXR) and the G protein–coupled receptor TGR5, INT-767, reverses age-related kidney disease in mice (2017) (36)
Selective in vivo inhibition of T cell activation by class II MHC-binding peptides administered in soluble form. (1990) (36)
Vitamin D Receptor Agonists in the Treatment of Autoimmune Diseases: Selective Targeting of Myeloid but Not Plasmacytoid Dendritic Cells (2007) (36)
The involvement of IL‐12 in murine experimentally induced autoimmune thyroid disease (1999) (36)
The vitamin D analogue BXL-628 inhibits growth factor-stimulated proliferation and invasion of DU145 prostate cancer cells (2006) (36)
Selective vitamin D receptor modulators and their effects on colorectal tumor growth (2007) (35)
Targeting IL-12, the key cytokine driving Th1-mediated autoimmune diseases. (1997) (35)
Antigen-Based Therapies Using Ignored Determinants of β Cell Antigens Can More Effectively Inhibit Late-Stage Autoimmune Disease in Diabetes-Prone Mice1 (2005) (35)
MHC: orchestrating the immune response. (1995) (35)
Anti-fibrotic effects of chronic treatment with the selective FXR agonist obeticholic acid in the bleomycin-induced rat model of pulmonary fibrosis (2017) (35)
TGR5 activation induces cytoprotective changes in the heart and improves myocardial adaptability to physiologic, inotropic, and pressure‐induced stress in mice (2018) (34)
1a,25-Dihydroxyvitamin D3 Inhibits Differentiation, Maturation, Activation, and Survival of Dendritic Cells Leading to Impaired Alloreactive T Cell Activation (2000) (33)
Regulation of the IL‐12 receptor β2 subunit by soluble antigen and IL‐12 in vivo (1998) (33)
A 1 , 25-Dihydroxyvitamin D 3 Analog Enhances Regulatory T-Cells and Arrests Autoimmune Diabetes in NOD Mice (2002) (33)
Pyrazole[3,4-e][1,4]thiazepin-7-one derivatives as a novel class of Farnesoid X Receptor (FXR) agonists. (2012) (33)
The mode of protein antigen administration determines preferential presentation of peptide-class II complexes by lymph node dendritic or B cells. (1997) (32)
Vitamin D receptor agonists, cancer and the immune system: an intricate relationship. (2006) (32)
Immunomodulatory effects of BXL-01-0029, a less hypercalcemic vitamin D analogue, in human cardiomyocytes and T cells. (2009) (31)
INT-767 prevents NASH and promotes visceral fat brown adipogenesis and mitochondrial function. (2018) (31)
Production of antigen-specific suppressive T cell factor by radiation leukemia virus-transformed suppressor T cells. (1981) (30)
Synthesis and anti-inflammatory properties of 1alpha,25-dihydroxy-16-ene-20-cyclopropyl-24-oxo-vitamin D3, a hypocalcemic, stable metabolite of 1alpha,25-dihydroxy-16-ene-20-cyclopropyl-vitamin D3. (2009) (29)
Apoptosis: potential for disease therapies. (1998) (29)
The motif for peptide binding to the insulin-dependent diabetes mellitus-associated class II MHC molecule I-Ag7 validated by phage display library. (2000) (29)
Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH (2019) (28)
Prevention of chronic allograft rejection by Vitamin D receptor agonists. (2005) (28)
Chemical immunology and allergy (2003) (28)
Prostate autoimmunity: from experimental models to clinical counterparts (2009) (27)
Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators. (2012) (26)
Immune deviation towards Th2 inhibits Th-1-mediated autoimmune diabetes. (1997) (26)
B Cells Present Antigen to CD4+ T Cells, but Fail to Produce IL‐12 Selective APC for Th2 Cell Development? (1997) (26)
The Role of IL‐12 in the Pathogenesis of Thl Cell‐Mediated Autoimmune Diseases (1996) (25)
Non-MHC-linked Th2 cell development induced by soluble protein administration predicts susceptibility to Leishmania major infection. (1997) (25)
Endogenous Interleukin-12 Is Critical for Controlling the Late but Not the Early Stage of Leishmania mexicana Infection in C57BL/6 Mice (2002) (24)
Pre-clinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol) (2006) (23)
Defective antigen presentation by macrophages from mice genetically selected for low antibody response (1981) (23)
Selective Immunointervention in Autoimmune Diseases: Lessons from Multiple Sclerosis (2001) (23)
Des (1-3) IGF-I-stimulated growth of human stromal BPH cells is inhibited by a vitamin D3 analogue (2002) (23)
Selection of Similar Naive T Cell Repertoires but Induction of Distinct T Cell Responses by Native and Modified Antigen1 (2004) (23)
Immunoregulation in senescence: increased inducibility of antigen-specific suppressor T cells and loss of cell sensitivity to immunosuppression in aging mice. (1982) (21)
Calcitriol derivatives with two different side chains at C-20 III. An epimeric pair of the gemini family with unprecedented antiproliferative effects on tumor cells and renin mRNA expression inhibition (2007) (20)
Impaired antigen presentation by murine I-Ad class II MHC molecules expressed in normal and HLA-DM-defective human B cell lines. (1997) (20)
Cardiopulmonary protective effects of the selective FXR agonist obeticholic acid in the rat model of monocrotaline-induced pulmonary hypertension (2017) (20)
Immunoregulation in Aging a (1988) (20)
Age restriction in antigen-specific immunosuppression. (1987) (20)
IL‐12 receptor regulation in IL‐12‐deficient BALB / c and C57BL / 6 mice (2000) (20)
Thiol antioxidants inhibit the formation of the interleukin-12 heterodimer: a novel mechanism for the inhibition of IL-12 production. (2002) (20)
Vaccine T-cell epitope selection by a peptide competition assay. (1989) (19)
Farnesoid X receptor activation improves erectile dysfunction in models of metabolic syndrome and diabetes. (2011) (19)
Rearrangement and expression of the alpha- and beta-chain genes of the T-cell antigen receptor in functional murine suppressor T-cell clones. (1985) (19)
A miniaturized in vitro diffusion culture system. (1978) (18)
Selective immunosuppression of class II-restricted T cells by MHC class II-binding peptides. (1993) (18)
Biological effects of Escherichia coli lipopolysaccharide (LPS) in vivo. I. Selection in the mouse thymus of killer and helper cells. (1976) (18)
Vitamin D receptor agonists as anti-inflammatory agents (2007) (18)
Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model (2020) (17)
Analysis of lysozyme‐specific immune responses by synthetic peptides. I. Characterization of antibody and T cell‐mediated responses to the N‐terminal peptide of hen egg‐white lysozyme (1986) (17)
Selective immunosuppression by administration of major histocompatibility complex class II-binding peptides. II. Preventive inhibition of primary and secondary in vivo antibody responses (1993) (17)
A microcomputer program for hydrophilicity and amphipathicity analysis of protein antigens. (1986) (17)
Vitamin D receptor polymorphisms in primary biliary cirrhosis: a functional connection? (2009) (16)
Biological effects of Escherichia coli lipopolysaccharide (LPS) in vivo. II. Selection in the mouse thymus of PHA- and con A-responsive cells. (1976) (16)
Fine antigenic specificity and genetic restriction of lysozyme‐specific suppressor T cell factor produced by radiation leukemia virus‐transformed suppressor T cells (1982) (16)
Comparison between VDR analogs and current immunosuppressive drugs in relation to CXCL10 secretion by human renal tubular cells (2010) (16)
MHC class II molecules bind indiscriminately self and non-self peptide homologs: effect on the immunogenicity of non-self peptides. (1993) (15)
Bile acids deoxycholic acid and ursodeoxycholic acid differentially regulate human β‐defensin‐1 and ‐2 secretion by colonic epithelial cells (2017) (15)
Enhancement of helper and suppressor T cell activities by thymosin α1 injection in old mice (1985) (15)
A gene therapy approach to treat demyelinating diseases using nonreplicative herpetic vectors engineered to produce cytokines (1998) (15)
Inhibition of costimulatory pathways for T-cell activation by 1,25-dihydroxyvitamin D(3). (2001) (15)
Structural requirements for the interaction between class II MHC molecules and peptide antigens (1990) (15)
CHAPTER 36 – Regulation of Immune Responses by Vitamin D Receptor Ligands (2005) (15)
Inhibition of T cell response with peptides is influenced by both peptide‐binding specificity of major histocompatibility complex molecules and susceptibility of T cells to blocking (1989) (14)
Co-dominant restriction by a mixed-haplotype I-A molecule (alpha k beta b) for the lysozyme peptide 52-61 in H-2k x H-2b F1 mice. (1990) (14)
IL-12 Administration Reveals Diabetogenic T Cells in Genetically Resistant I-Eα-Transgenic Nonobese Diabetic Mice: Resistance to Autoimmune Diabetes Is Associated with Binding of Eα-Derived Peptides to the I-Ag7 Molecule1 (2001) (14)
Calcitriol derivatives with two different side-chains at C-20. Part 4: further chain modifications that alter VDR-dependent monocytic differentiation potency in human leukemia cells. (2007) (13)
Obeticholic acid ameliorates dyslipidemia but not glucose tolerance in mouse model of gestational diabetes (2019) (13)
Inhibition of T cell activation by MHC blockade. (1990) (13)
Immunoregulation of lysozyme‐specific suppression. II. Hen egg‐white lysozyme‐specific monoclonal suppressor T cell factor suppresses the afferent phase of delayed‐type hypersensitivity and induces second‐order suppressor T cells (1984) (13)
Beneficial effects of bile acid receptor agonists in pulmonary disease models (2017) (13)
Selective immunosuppression. (1993) (13)
Antitumorigenic and antiinsulinogenic effects of calcitriol on insulinoma cells and solid beta-cell tumors. (2002) (12)
C-20 cyclopropyl vitamin D3 analogs. (2006) (12)
A peptide binding motif for I-Eg7, the MHC class II molecule that protects E alpha-transgenic nonobese diabetic mice from autoimmune diabetes. (1999) (12)
Tolerance Mofetil Treatment Mediate Transplantation and Mycophenolate 3 , 25-Dihydroxyvitamin D α Regulatory T Cells Induced by 1 (2001) (12)
Induction of transplantation tolerance by 1,25-dihydroxyvitamin D(3). (2001) (12)
Calcitriol derivatives with two different side chains at C-20 24-Hydroxy derivatives as metabolic products and molecular probes for VDR exploration (2004) (12)
35th Annual meeting of the European Association for the Study of Diabetes. Brussels, Belgium, 28 September-2 October, 1999. Abstracts. (1999) (11)
Antigen presentation and self-nonself discrimination. (1990) (11)
Metabolic Profile of Obeticholic Acid and Endogenous Bile Acids in Rats with Decompensated Liver Cirrhosis (2017) (11)
Enhancement of suppressor T cell activity by injection of anti-IFN-gamma monoclonal antibody. (1988) (11)
Monoclonal suppressor T-cell factor displaying VH restriction and fine antigenic specificity (1983) (10)
Differential major histocompatibility complex-related activation of idiotypic suppressor T cells. Suppressor T cells cross-reactive to two distantly related lysozymes are not induced by one of them (1980) (10)
Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH (2019) (10)
Calcitriol derivatives with two different side chains at C-20. II. Diastereoselective syntheses of the metabolically produced 24(R)-hydroxygemini. (2004) (10)
Disulfide‐linked surface molecules of monoclonal antigen‐specific suppressor T cells: evidence for T cell receptor structures (1985) (10)
Transplantation tolerance by 1,25-dihydroxyvitamin D(3)-induced costimulation blockade. (2001) (10)
Spontaneous lymphomas in mice genetically selected for high or low phytohemagglutinin responsiveness. (1985) (9)
Therapeutic effects of obeticholic acid (OCA) treatment in a bleomycin-induced pulmonary fibrosis rat model (2018) (9)
The farnesoid X receptor agonist obeticholic acid upregulates biliary excretion of asymmetric dimethylarginine via MATE-1 during hepatic ischemia/reperfusion injury (2018) (9)
Characterization of five 19-nor-analogs of 1α,25(OH)2-Vitamin D3 with 20-cyclopropyl-modified side-chains: implications for ligand binding and calcemic properties (2004) (9)
Local structure of a peptide contact site on Ak alpha. (1991) (9)
Therapeutic effects of the selective farnesoid X receptor agonist obeticholic acid in a monocrotaline-induced pulmonary hypertension rat model (2019) (8)
Control of Adaptive Immunity by Vitamin D Receptor Agonists (2011) (8)
The presentation of antigen by MHC class II molecules. (1989) (8)
LACK OF INFLUENCE OF CYCLOSPORINE ON ANTIGEN PRESENTATION TO LYSOZYME‐SPECIFIC T CELL HYBRIDOMAS (1988) (8)
Induction of azobenzenearsonate- (ABA) specific helper and suppressor T cells and in vitro evaluation of their activities in the antibody response to T-dependent ABA-protein conjugates. (1981) (8)
Immunoregulation of lysozyme‐specific suppression. I. Induction and suppression of delayed‐type hypersensitivity to hen egg‐white lysozyme (1984) (7)
MHC blocking peptides and T-cell receptor antagonists: novel paths to selective immunosuppression? (1995) (7)
DRα: Eβ heterodimers in DRA transgenic mice hinder expression of Eα:Eβ molecules and are more efficient in antigen presentation (1995) (7)
From Basic Immunology to Immune-Mediated Demyelination (1999) (7)
Testosterone protects the lower urinary tract from metabolic syndrome-induced alterations (2012) (6)
The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inﬂammation, ﬁbrosis, and proteinuria (2009) (6)
Immunosuppression by cell‐free translation products from monoclonal antigen‐specific suppressor T cell mRNA (1985) (6)
Life-span, tumor incidence, and natural killer cell activity in mice selected for high or low antibody responsiveness. (1984) (6)
Inhibition of Type 1 Diabetes Development by Vitamin D Receptor Agonists (2005) (6)
Inhibition of T cell activation by MHC blockade: a possible strategy for immunointervention in autoimmune diseases. (1992) (6)
T cell receptor‐homologous mRNA from a suppressor T cell clone directs the synthesis of antigen‐specific suppressive products (1987) (6)
IDIOTYPY AND ANTIGENIC SPECIFICITY OF T h , T s , AND B CELLS INDUCED BY HEN EGG-WHITE LYSOZYME (1979) (6)
Selective inhibition of T cell responses by protein and peptide-based immunotherapy. (1993) (5)
Obeticholic acid reduces biliary and hepatic matrix metalloproteinases activity in rat hepatic ischemia/reperfusion injury (2020) (5)
Selective suppression of T-cell activation by administration of MHC class II-binding peptides. (1992) (5)
Dendritic Cells Production by Myeloid and Plasmacytoid Cutting Edge: Differential Chemokine (2013) (5)
Human prostatic urethra expresses vitamin D receptor and responds to vitamin D receptor ligation. (2010) (5)
Peptide binding and editing: generation of TCR ligands. (1998) (5)
Partial overlap of Ir gene-controlled responses to two proteins of limited relatedness: hen egg-white lysozyme and human lysozyme. (1980) (4)
Reconstitution of T cell functions in aging mice by thymosin alpha 1. (1986) (4)
Human prostatic urethra expresses vitamin D receptor and responds to vitamin D receptor ligation (2010) (4)
Computerized data analysis in cellular immunology. Enhancement and suppression of immune responses. (1988) (4)
Enterohepatic Takeda G-Protein Coupled Receptor 5 Agonism in Metabolic Dysfunction-Associated Fatty Liver Disease and Related Glucose Dysmetabolism (2022) (4)
Inhibition of T cell activation by blockade of MHC class II molecules. (1991) (4)
Obeticholic acid improves fetal bile acid profile in a mouse model of gestational hypercholanemia (2020) (4)
CHAPTER 28 – Dendritic cells in the central nervous system (2001) (4)
Immunoregulation of lysozyme-specific suppression. III. Epitope-specific amplification of immunosuppression induced by monoclonal suppressor-T-cell products. (1986) (3)
109: Spontaneous and Induced Autoimmune Prostatitis in the Non-Obese Diabetic Mouse (2006) (3)
Inhibition of dendritic cell costimulation associated with tolerance to allografts. (2000) (3)
P1155 : FXR Agonism with obeticholic acid may attenuate bone mineral density decrease in subjects with primary biliary cirrhosis (2015) (3)
IL-12-Deficient Mice (2003) (3)
Cell selection in the thymus of mice treated with escherichia coli lipopolysaccharide (LPS). (1976) (3)
Autoimmune Diabetes-Transgenic Nonobese Diabetic Mice from α Class II Molecule That Protects E , the MHCg 7 A Peptide Binding Motif for I-E (1999) (3)
Effects of whole-body irradiation on antibody affinity. (1977) (3)
Establishment of functional, antigen-specific T cell lines by radLV-induced transformation of murine T lymphocytes. (1982) (3)
Inhibition of AUTOTAXIN by bile salts and bile salt-like molecules increases its expression by feedback regulation. (2021) (3)
An Apple IIE microcomputer program for multiple non-independent comparisons by the Scheffe's test. (1989) (3)
1114 FUNCTIONAL CHARACTERIZATION OF THE SEMI-SYNTHETIC BILE ACID DERIVATIVE INT-767, A DUAL FXR AND TGR5 AGONIST (2010) (3)
Farnesoid X receptor activation by the novel agonist TC-100 (3α, 7α, 11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid) preserves the intestinal barrier integrity and promotes intestinal microbial reshaping in a mouse model of obstructed bile acid flow. (2022) (3)
The role of endogenous IL12 in the induction of Th1-cell-mediated autoimmune diseases. (1995) (3)
Megatrends in bile acid receptor research (2017) (2)
MHC: AN INTEGRATED GENETIC SYSTEM WHICH ORCHESTRATES THE IMMUNE RESPONSE. (1995) (2)
Chronic Immuno-Mediated Inflammation Stromal Cells As Inducers and Targets of Human Benign Prostatic Hyperplasia (2009) (2)
The Fine Specificity of Regulatory T Cells (1979) (2)
Enhancement of helper and suppressor T cell activities by thymosin alpha 1 injection in old mice. (1985) (2)
Selective immunosuppression : basic concepts and clinical applications (1994) (2)
A highly sensitive enzyme-linked immunosorbent assay for idiotype-bearing antibodies. (1984) (2)
A Dual Agonist of Farnesoid X Receptor (FXR) and the G protein-coupled Receptor TGR5, INT-767, Slows Down Age-Related Kidney Disease in Mice (2017) (2)
Pharmacological induction of tolerogenic dendritic cells and (2004) (2)
Candida albicans Mice upon Protective Th 1 Responses in IL-12-Deficient IL-10 Is Required for Development of Luciano Adorini and Luigina Romani (1998) (2)
HIGH FREQUENCY OF SPECIFIC ANTIGEN BINDING CELLS IN PROTEIN ANTIGEN STIMULATED LYMPH NODES (1979) (2)
Thymosin α1-induced modulation of immunoregulatory T-Lymphocyte activities (1984) (2)
Immunoadsorbent removal of antibodies produced during in vitro culture relieves inhibition of the response. (1979) (2)
Antigen-based immunointervention in human autoimmune diseases. (2004) (2)
Pathogenic and protective T-cell responses in autoimmune diseases. (1998) (2)
Expression of T-cell receptor by a mouse monoclonal antigen-specific suppressor T-cell line. (1986) (1)
Leukocyte migration to pancreatic islets: a critical step in the pathogenesis of type 1 diabetes (2006) (1)
HP-01-006 The dual FXR/TGR5 agonist INT-767 counteracts nonalcoholic steatohepatitis and erectile dysfunction in a rabbit model of high fat diet-induced metabolic syndrome (2017) (1)
Basic strategies of the immune system in the regulation of antibody response (1980) (1)
Faculty Opinions recommendation of The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors. (2009) (1)
The role of FXR and TGR5 in reversing and preventing progression of Western diet–induced hepatic steatosis, inflammation, and fibrosis in mice (2022) (1)
DR alpha: E beta heterodimers in DRA transgenic mice hinder expression of E alpha: E beta molecules and are more efficient in antigen presentation. (1995) (1)
Peptide interactions with MHC class II molecules. (1991) (1)
The Italian Society of Immunology: past, present and future (2010) (1)
Alternatively Activated Dendritic Cells Cutting Edge: Proangiogenic Properties of (2005) (1)
OC.03.4 EFFICACY AND SAFETY OF OBETICHOLIC ACID IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS: AN ANALYSIS OF THE ITALIAN PATIENTS FROM A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY (2016) (1)
Antigen-based immunointervention in autoimmune diseases. (1997) (1)
Synthetic peptides in the analysis of the induction and regulation of delayed-type hypersensitivity to lysozyme. (1985) (1)
913 THERAPEUTIC EFFECTS OF FXR AND TGR5 ACTIVATION IN THE MDR2 (ABCB4)−/− MOUSE MODEL OF SCLEROSING CHOLANGITIS (2010) (1)
A BASIC microcomputer program for data analysis of limiting dilution assays (1989) (1)
Suppression of T-cell activation by administration of MHC class II-binding peptides. (1993) (1)
THE ANTIGEN BRIDGE AND IDIOTYPIC INTERACTIONS AS PARALLEL COMMUNICATION SYSTEMS (1980) (1)
Faculty Opinions recommendation of Identification of regulatory T cells in tolerated allografts. (2002) (1)
Selective Immunosuppression by Administration of Major Histocompatibility Complex Class H-binding Peptides. 1I. Preventive Inhibition of Primary and Secondary In Vivo Antibody Responses By Jean-Charles Gu6ry, Monica Neagu, (1993) (1)
1451: Human Prostate Cells as Inducers and Targets of Chronic Autoimmune Inflammation (2006) (1)
Selective immunosuppression. (1993) (1)
Mice upon Candida albicans Infection Protective Th1 Responses in IL-12-Deficient IL-10 Is Required for Development of (2013) (1)
2 HIGH SERUM AUTOTAXIN ACTIVITY PREDISPOSES TO SEVERE PRURITUS DURING TREATMENT WITH OBETICHOLIC ACID IN PRIMARY BILIARY CIRRHOSIS (2011) (1)
Elevated body mass index correlates with higher seminal interleukin 8 levels and ultrasound prostate abnormalities in infertile men (2012) (1)
RECK- and TIMP-mediated downregulation of matrix metalloproteinase activity by obeticholic acid in hepatic ischemia/reperfusion (2020) (1)
Advances in selective immunosuppression. (1995) (1)
Dendritic Cell Modulation by the Vitamin D System (2012) (1)
SAT-337-Evaluation of anti-fibrotic properties of OCA and INT-767 in an in vitro system of NAFLD (2019) (1)
Apoptosis, tolerance and immunoregulation - Integrated pathways for immune system homeostasis (1998) (1)
Exploiting the potential of regulatory T cells in the control of type 1 diabetes (2005) (1)
REGULATION OF ANTIBODY AFFINITY IN THE MOUSE: AGE-RELATED CELLULAR ASPECTS (1981) (1)
IL-12 (Preliminary Pages) (1997) (1)
Grammars, Machines, and Immunoregulatory Cell Interactions. An Exercise in Immunosemiotics (1988) (1)
IMMUNE RESPONSIVENESS AND INCIDENCE OF RETICULUM CELL SARCOMA IN LONG‐TERM SYNGENEIC RADIATION CHIMERAS (1976) (1)
OC.12.8 LONG-TERM SAFETY OF OBETICHOLIC ACID IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS (2016) (1)
Immunosuppression by MHC Class II Blockade (1992) (1)
Faculty Opinions recommendation of IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. (2007) (1)
Antigen presentation and IL-12 production by dendritic cells in vivo. (1997) (1)
Sa.96. A Novel Vitamin D Analog has a Profound Effect in Generating Potent Immunomodulatory Dendritic Cells (2008) (0)
Selective Immunosuppression: Where Are We Now, and Where Are We Going? (1995) (0)
Vitamin D Receptor Agonist Elocalcitol Prostatitis in Nonobese Diabetic Mice by the Treatment of Experimental Autoimmune (2006) (0)
The cytokine network in action (2002) (0)
Obeticholic acid improves fetal hypercholanaemia during cholestatic gestation (2018) (0)
Not Plasmacytoid Dendritic Cells Modulates Tolerogenic Properties in Myeloid Selectively 31 , 25-Dihydroxyvitamin (2006) (0)
Upregulation of MATE-1 transporter by obeticholic acid correlates with increased biliary excretion of asymmetric dimethylarginine during hepatic ischemia/reperfusion injury (2017) (0)
Th1 induce and Th2 cells inhibit antigen-dependent IL-12 secretion by dendritic cells. (1998) (0)
Faculty Opinions recommendation of Immunoregulatory mechanisms triggered by viral infections protect from type 1 diabetes in mice. (2009) (0)
Immunological aspects of male accessory gland infection (2010) (0)
1349: Inhibition of Spontaneous and Androgen-Induced Prostate Growth by a Nonhypercalcemic Calcitriol Analogue (2004) (0)
Faculty Opinions recommendation of IL-25 regulates Th17 function in autoimmune inflammation. (2007) (0)
Design, synthesis, molecular modeling and biological activity of chenodeoxycholic acid carbamate derivatives as potent and selective FXR agonists (2010) (0)
Treatment of Immunomediated Diseases by Vitamin D Analogs (2010) (0)
Cytokines and autoimmune diseases (edited by VK Kuchroo et al.) (2002) (0)
Faculty Opinions recommendation of Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. (2007) (0)
Further increase in biliary excretion of asymmetric dimethylarginine during hepatic ischemia/reperfusion injury by obeticholic acid, a farnesoid-X-receptor agonist (2016) (0)
Faculty Opinions recommendation of IL-17 regulates adipogenesis, glucose homeostasis, and obesity. (2010) (0)
SAT-389-Obeticholic acid reduces matrix metalloproteinases activity via iNOS modulation in hepatic ischemia/reperfusion injury (2019) (0)
Altered ethanol metabolism and increased oxidative stress enhance alcohol‐associated liver injury in farnesoid X receptor‐deficient mice (2022) (0)
Faculty Opinions recommendation of Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. (2012) (0)
LIVER Ef fi cacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid (2015) (0)
The Antigenic Structure of Lysozyme as Detected by T-cells (1989) (0)
The nonobese diabetic (NOD) mouse as a model for insulin-dependent diabetes mellitus (1996) (0)
UPREGULATION OF L-TYPE CA2+ CHANNEL ACTIVITY BY THE VDR AGONIST ELOCALCITOL IN HUMAN AND RAT BLADDER (2008) (0)
Fxr But Not Tgr5 Activation Stimulates Hco3-Rich Bile Secretion And Ameliorates Liver Damage In Mdr2-/- (Abcb4-/-) Mouse Model Of Chronic Liver Injury (2011) (0)
ActivationAntigen Processing and in Th1 But Not Th2 Cell Microglia Are More Efficient Than Astrocytes in (1998) (0)
Protocol for diversion of a CD4+ response to the T-helper 2 cell pathway. (2001) (0)
Dendritic Cell Manipulation with Biological and Pharmacological Agents to Induce Regulatory T Cells (2008) (0)
OC.06.8 INTEGRATED ANALYSIS OF EFFICACY OF PHASE II AND III DATA OF OBETICHOLIC ACID IN PBC SUBPOPULATIONS BASED ON AGE AND SEX (2016) (0)
Using an analog of vitamins d3 for the treatment of autoimmune diabetes (2002) (0)
Faculty Opinions recommendation of In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-alpha. (2009) (0)
!!~ii~!!iiiiiiiii!iiii~ii!iii!!!i!iii!~ ~~ili!i Selective immunosuppression (1993) (0)
The dual FXR/TGR5 agonist INT-767 reduces visceral fat mass, promoting preadipocyte brown differentiation, mitochondrial function and insulin sensitivity in a rabbit model of high fat diet-induced metabolic syndrome (2016) (0)
T cell independent induction of antigen specific suppression of the antibody response (1979) (0)
Induction of Peripheral Tolerance in Primed Mice (1994) (0)
Obeticholic acid reduces hepatic matrix metalloproteinase activity in a diet-induced ob/ob mouse model of NASH (2022) (0)
Increase in transporter MATE-1 expression induced by obeticholic acid correlates with higher biliary excretion of asymmetric dimethylarginine during hepatic ischemia/reperfusion injury (2017) (0)
Ileal and Colonic Enteroids as a Model for Studying FXR Regulation of the Enterohepatic Circulation in Humans (2020) (0)
Dendrit ic Cells but N o t B Cells Present Antigenic Complexes to Class II-restricted T Cells after Administrat ion o f Protein in Adjuvant By (2003) (0)
Nonalcoholic Fatty Liver Disease Hepatic Monocyte Activity and Improves Bile Acid Receptor Activation Modulates Immunology : (2013) (0)
Title Pages / Table of Contents (1994) (0)
A comparison of cytokine-based approaches to treat autoimmune disorders (2004) (0)
4 Testosterone protects from metabolic syndrome-associated prostate inflammation: An experimental study in rabbit (2012) (0)
Sa1657 FXR and/or TGR5 Bile Acid Receptor Agonists Differently Ameliorate Liver Injury and Steatosis After Acute Binge or Prolonged Alcohol Feeding in Mice (2016) (0)
Central nervous system delivery of interleukin-4 using herpetic vectors ameliorates experimental allergic encephalomyelitis (1998) (0)
Obeticholic Acid Reduces Kidney Matrix Metalloproteinase Activation Following Partial Hepatic Ischemia/Reperfusion Injury in Rats (2022) (0)
Contents, Vol. 99, 1992 (1992) (0)
Interleukin 12 is critical in the development of experimental autoimmune myasthenia gravis (1998) (0)
Faculty Opinions recommendation of Vitamin D3 attenuates Th2 responses to Aspergillus fumigatus mounted by CD4+ T cells from cystic fibrosis patients with allergic bronchopulmonary aspergillosis. (2010) (0)
Disease in Diabetes-Prone Mice Effectively Inhibit Late-Stage Autoimmune Cell Antigens Can More b Determinants of Antigen-Based Therapies Using Ignored (2005) (0)
Prostatitis in the Nonobese Diabetic Mouse Protein Peptide-Induced Autoimmune Spontaneous and Prostatic Steroid Binding (2007) (0)
299 - FXR-Dependent Modification of the Human Small Intestinal Microbiome (2018) (0)
Cells in Autoimmune Diabetes Development Dynamics of Pathogenic and Suppressor T (2013) (0)
OCA administration reduces lung matrix metalloproteinase activation following hepatic ischemia/reperfusion injury in rats (2021) (0)
HUMAN BENIGN PROSTATIC HYPERPLASIA CELLS AS INDUCERS AND TARGETS OF CHRONIC AUTOIMMUNE INFLAMMATION (2008) (0)
Testosterone protects from metabo lic syndrome-associated prostate inflammation: an experimental study in rabbit (2011) (0)
Title Page / Contents / Selective Immunosuppression: Where Are We Now, and Where Are We Going? (1995) (0)
Spreading Determines the Hierarchy of Determinant The Frequency of High Avidity T Cells (2001) (0)
IL-12 administration prevents but does not break tolerance in Th1 cells (1997) (0)
Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH (2019) (0)
Beneficial effects of Vitamin D receptor agonists on retinal autoimmunity (131.30) (2007) (0)
Electron Microscopic Observations on T and B Lymphocytes from Spleens of Syngeneic Radiation Chimaeras (1976) (0)
111: Up-Regulation of Rho-Kinase-Associated Proteins and Altered Nerve-Mediated Functions in Experimental Autoimmune Prostatitis (2006) (0)
VITAMIN D3 INHIBITS EXPRESSION OF COSTIMULATORY MOLECULES ON DENDRITIC CELLS AND THEIR CAPACITY TO STIMULATE ALLOREACTIVE T CELLS (1999) (0)
The FXR agonist obeticholic acid decreases matrix metalloproteinase activity via RECK and TIMP modulation in hepatic ischemia/reperfusion injury (2020) (0)
Immunoregulation of “In Vitro” Antibody Response to Azobenzenearsonate (ABA)-Proteins (1983) (0)
Referees (2002) (0)
Autoimmune mechanisms (SY2-2) Chairpersons: Shigekazu Nagata, Betty Diamond (2010) (0)
Faculty Opinions recommendation of Lamina propria macrophages and dendritic cells differentially induce regulatory and interleukin 17-producing T cell responses. (2007) (0)
Vitamin D Receptor Agonists Can Prevent and Treat Experimental Autoimmune Uveoretinitis (2006) (0)
Interspersed repetitive L1 family is differentially transcribed during the murine thymus ontogeny (1987) (0)
Acknowledgement to Referees 2005 (2005) (0)
196 Monocyte-Dependent and -Independent Modulatory Effects of Vitamin D3 on X4 and R5 HIV-1 Replication in IL-2 Stimulated PBMC (2009) (0)
Atorvastatin but not elocalcitol increases sildenafil responsiveness in Spontaneously Hypertensive 1 Rats by regulating the RhoA / ROCK pathway 2 Running title : Atorvastatin and sildenafil in SHR 3 1 (2007) (0)
Induction of Selective Immunosuppression by Administration of MHC Class II Binding Peptides (1993) (0)
Vitamin D3 analogue for use in the treatment of BPH (2003) (0)
Pathogenetic Mechanisms of Autoimmunity (1999) (0)
but Not Plasmacytoid Dendritic Cells Modulates Tolerogenic Properties in Myeloid 1,25-Dihydroxyvitamin D3 Selectively (2013) (0)
Mapping of Antigen Epitopes Interacting with Class II MHC Products and with the Antigen Receptor of T Lymphocytes (1987) (0)
Abstracts ‐ Thurday 26th July 2001 (2001) (0)
Immunotherapy of Autoimmune Disease. (1992) (0)
A basic library of microcomputer programs to obtain immunologically relevant information from protein sequences. (1988) (0)
Obeticholic acid restores hepatic RECK content in a diet-induced ob/ob mouse model of NASH (2022) (0)
1580 TESTOSTERONE PROTECT FROM PROSTATIC INFLAMMATION RELATED TO METABOLIC SYNDROME AN EXPERIMENTAL STUDY IN AN ANIMAL MODEL (2012) (0)
INOS-mediated decrease of matrix metalloproteinase activity by obeticholic acid in hepatic ischemia/reperfusion (2019) (0)
Abstract 435: Hepatic Carboxylesterase 1 is Essential for Maintaining Hepatic Triglyceride and Plasma Cholesterol Homeostasis and is Regulated by the Farnesoid X Receptor (2013) (0)
Approaches toward peptide-based immunotherapy of autoimmune diseases (2004) (0)
Astrocytes as Th2-promoting APC in the central nervous system☆ (1997) (0)
The dual FXR/TGR5 agonist INT-767 counteracts nonalcoholic steatohepatitis and visceral adipose tissue dysfunction in a rabbit model of high fat diet-induced metabolic syndrome (2017) (0)
Non-MHC-linked genetic polymorphism controls selective development of Th2 but not inhibition of Th1 cells by soluble antigen administration. (1999) (0)
Vitamin D Receptor Agonists in the Treatment of Benign Prostatic Hyperplasia (2011) (0)
The Farnesoid-X-Receptor Agonist Obeticholic Acid Further Increases Biliary Excretion of Asymmetric Dimethylarginine during Hepatic Ischemia/Reperfusion Injury (2016) (0)
Maturing Dendritic Cells Unique Regulation of CCL18 Production by (2017) (0)
Protein 2 , an Autoantigen in Type 1 Diabetes Phosphatase-Like Insulinoma-Associated Diabetic Mice to the Tyrosine Early Th 1 Response in Unprimed (2000) (0)
190: BXL-628, a Vitamin D Analog, Decreases RHOA/ROK Signalling in Rat and Human Bladder (2006) (0)
Faculty Opinions recommendation of Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. (2013) (0)
Prevention of type 1 diabetes: Where do we start? (2003) (0)
SAT-342-Morphometric collagen analysis discerns anti-fibrotic effects of INT-767 and OCA in NASH mouse models using second harmonic generation imaging (2019) (0)
Obeticholic acid reduces lipid accumulation and fibrosis in a diet-induced ob/ob mouse model of NASH (2023) (0)
Fine Specificity of H-2-Restricted, Lysozyme Specific Suppressor T Cell Factor (1983) (0)
T cell reconstitution by thymic hormones in aging (1987) (0)
Immunosuppression by MHC blockade (1992) (0)
Expression and regulation of T cell costimulatory signals in glial cells of the central nervous system (1996) (0)
Microglia and astrocytes as regulators of Th1 and Th2 responses (1998) (0)
Deconstructing bile acid signaling pathways (2011) (0)
Faculty Opinions recommendation of CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. (2004) (0)
Compound and use in therapy. (2004) (0)
Faculty Opinions recommendation of Phenotype, localization, and mechanism of suppression of CD4(+)CD25(+) human thymocytes. (2002) (0)
Analysis of the Efficacy of OCA in Primary Biliary Cholangitis by Baseline Biochemistry Across Three Randomized, Double-Blind, Placebo-Controlled Clinical Trials: 751 (2016) (0)
The FXR agonist obeticholic acid normalizes lipid droplet and triglyceride handling in visceral adipose tissue preadipocytes from a non-genomic rabbit model of metabolic syndrome (2013) (0)
The dual FXR/TGR5 agonist INT-767 counteracts nonalcoholic steatohepatitis in a rabbit model of high fat diet-induced metabolic syndrome (2016) (0)
UDCA and INT-777 suppress cardiac fibrosis triggered by IL- 11 through involvement of TGR5 (2022) (0)
Native and Modified Antigen but Induction of Distinct T Cell Responses by Selection of Similar Naive T Cell Repertoires (2004) (0)
THE CELLS OF THE IMMUNE SYSTEM, AN UPDATE ON THEIR INTERACTIONS AND SIGNALS (1987) (0)
Synthetic peptides in the analysis of T cell interactions. (1984) (0)
New trends in clinical and experimental immunosuppression--fourth international conference. 17-20 February 2000, Geneva, Switzerland. (2000) (0)
Faculty Opinions recommendation of Liver X receptor (LXR) mediates negative regulation of mouse and human Th17 differentiation. (2011) (0)
Use of 1-alpha-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-cholecalciferol for the treatment of benign prostatic hyperplasia (2004) (0)
OC.06.1 ANALYSIS OF THE EFFICACY OF OCA IN PRIMARY BILIARY CIRRHOSIS BY VARYING PATIENT DISEASE SEVERITY ACROSS THREE RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIALS (2016) (0)
Faculty Opinions recommendation of Homeostatic proliferation is a barrier to transplantation tolerance. (2004) (0)
Faculty Opinions recommendation of Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. (2001) (0)
PROCESSING OF AN ENDOGENOUS PROTEIN CAN GENERATE MHC CLASS THOSE DERIVED FROM EXOGENOUS ANTIGEN 11-RESTRICTED T CELL DETERMINANTS DISTINCT FROM (1991) (0)
Selective Immunosuppression by Administration of Major Histocompatibility Complex (MHC) Class H-binding Peptides. I. Evidence for In Vivo MHC Blockade Preventing T Cell Activation By Jean-Charles Gu6ry,* Alessandro Sette,~ Jonathan Leighton,* (1992) (0)
Differential effects of two-week treatment with atorvastatin or elocalcitol, two RhoA/ROK signalling modulators, on erectile function and sildenafil responsiveness in spontaneously hypertensive rats (2007) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Luciano Adorini?

Luciano Adorini is affiliated with the following schools:

Luciano Adorini's Academic­Influence.com Rankings

Luciano Adorini's Degrees

Similar Degrees You Can Earn

Why Is Luciano Adorini Influential?

Luciano Adorini's Published Works

Published Works

What Schools Are Affiliated With Luciano Adorini?

Luciano Adorini's AcademicInfluence.com Rankings